Doctors' prescription behaviour regarding dosage recommendations for preparations of kava extracts

Pharmacoepidemiology and Drug Safety

Volumn 12, Issue 5, 2003, Pages 417-421

  Dietlein, G ^a   Schroder Bernhardi D ^a  

^a IQVIA   (United States)

Author keywords

Dose recommendations; Longitudinal patient database; Prescribing behaviour; Under over dosage

Indexed keywords

ANTARES; ANTIDEPRESSANT AGENT; KAVA EXTRACT; KAVASPORAL FORTE;

ACCESS TO INFORMATION; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DEPRESSION; DRUG CAPSULE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; GERMANY; HUMAN; LONGITUDINAL STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; SIDE EFFECT; TABLET; VALIDATION PROCESS;

BEHAVIOR; DEPRESSION; HUMANS; KAVA; OVERDOSE; PHYSICIAN'S PRACTICE PATTERNS; PLANT EXTRACTS; PLANTS, MEDICINAL; TIME FACTORS;

EID: 0042871466     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.839     Document Type: Article

References (26)

1. Schröder-Bernhardi D, Dietlein G. Drug utilization research on the basis of a longitudinal patient database. J Clin Pharmacol Ther 2000; 38: 368.
2. Schröder-Bernhardi D, Dietlein G. Prescription behaviour of doctors regarding dosage recommendations. Pharmacoepidemiol Drug Safe 2001; 10: S31.
3. Jünger C, Rathmann W, Giani G. Prescribing conduct of general practitioners and internists by the diabetic therapy taking account of the drug budget. Dtsch Med Wochenschr 2000; 125: 103-109.
4. Rathmann W, Haastert B, Roseman J, Gries FA, Giani G. Prescription drug use and costs among diabetic patients in primary health care practices in Germany. Diabetes Care 1998; 21: 389-397.
5. Krobot KJ, Steinberg HW, Pfaffenrath V. Migraine prescription density and recommendations. Cephalalgia 1999; 19: 511-519.
6. Pittler MH, Ernst E. Efficacy of kava extract for treating anxiety: Systematic review and metaanalysis. J Clin Psychopharmacol 2000; 20: 84-89.
7. Tinsley JA. The hazards of psychotropic herbs. Minn Med 1999; 82: 29-31.
8. Garner LF, Klinger JD. Some visual effects caused by beverage kava. J Ethnopharmacol 1985; 13: 307-311.
9. Pepping J. Kava: Piper methysticum. Am J Health Syst Pharm 1999; 56: 957-960.
10. Review: Piper methysticum (kava kava). Altern Med Rev 1998; 3: 458-460.
11. Volz HP, Kieser M. Kava-kava extract versus placebo in anxiety disorders. Pharmacopsychiatry 1997; 30; 1-5.
12. Singh YN. Kava: An overview. J Ethnopharmacol 1992; 37: 13-45.
13. Matthews HB, Lucier GW, Fisher KD. Medicinal herbs in the United States: Research needs. Environ Health Perspect 1999; 107: 773-778.
14. Dietlein G, Schröder-Bernhardi D. Use of the MediPlus patient database in health care research. Int J Pharmacol Ther 2002; 40: 130-133.
15. Todd J, Lawrenson R, Farmer RD, Williams TJ, Leydon GM. A re-analysis with the MediPlus database. Hum Reprod 1999; 14: 1500-1505.
16. Rodriguez LA, Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45: 419-425.
17. Hann M, Baker D, Hayes J, Wagner A, Barr R. Methodological issues in the development of a national database for primary care groups and trust. Health Soc Care Community 2001; 9: 286-293.
18. Farmer RD, Lawrenson RA, Todd JC, Williams TJ, MacRae K. Analyses of the UK General Practice Research Database and the UK MediPlus database. Hum Reprod Update 1999; 5: 688-706.
19. Codina C, Corominas N, Roca M, et al. Comparative study of an expert system application in the prescription of medications. Med Clin (Barc) 1997; 109: 538-541.
20. Gibbs RG, Newson R, Lawrenson R, Greenhalgh RM, Davies AH. Experience of a national primary care database. Stroke 2001; 32: 1085-1090.
21. Hippius M, Humaid B, Sicker T, Hoffmann A, Gottler M, Hasford J. Adverse drug reaction monitoring - Digoxin overdose in elderly. Int J Clin Pharmacol Ther 2001; 39: 336-343.
22. Russmann S, Lauterburg BH, Helbling A. Kava hepatotoxicity. Ann Intern Med 2001; 135: 68-69.
23. Pittler MH, Edzard NA. Kava extract for treating anxiety (Cochrane review). Cochrane Database Syst Rev 2001; 4: CD003383.
24. Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), Pressemitteilung 10/2002, www.bfarm.de
25. Kumar J. The present status of the Kava industry. Kava Symposium Suva. Fiji, 6th November 2002.
26. Monheit L. Kava Under the Microscope in Europe and North America. NPI Watch Editorial, European Herbal Practitioners Association, 2002.